Innovent
Innovent including oncology
Innovent is a leading biotechnology company in China. It aims to produce highly complex and affordable biopharmaceutical products for patients. Since its inception, Innovent has established a product chain of 13 new drugs covering four major disease areas, including oncology, ophthalmology, autoimmune diseases and cardiovascular diseases, and has undertaken 7 National Science and Technology Projects, of which 5 products were selected for the National "Major New Drug Creation" Program and 1 product was selected for the National Key Research and Development Program. Special "Precision Medicine Research".
Shuoxing biological innovative nano multi antibody sm3321 was approved by ind in the United States
Temasek's reduction of Cinda biological
EqualOcean Sector Quarterly Report - Healthcare Sectors
To help worldwide investors keep track of what is happening in each industry or sector and the related hot spots, we launched the EqualOcean Sector Quarterly Report series, which gathers notable information and statistics in each quarter.
Apr 07, 2022 01:44 PM
Haizheng pharmaceutical and Junshi biology signed a contract for commissioned production of Xinguan oral drug vv116
Heavy bomb in the field of hypoglycemic! Lilly tirzepatide approved for listing
Research
Healthcare, Consumer Staples, TechnologyWIA2020 | Rising Tech Stars 2020: Global & China's 100
Research
Healthcare, Technology, Consumer DiscretionaryTech for Global, Globalization Footprints of the Established and the New
Roche PD-L1 combined with tigit failed in the first-line treatment of stage III non-small cell lung cancer with high expression of PD-L1
Foreign media said Green Valley pharmaceutical Alzheimer's disease new drug phase IX phase I ® The international phase III clinical trial has been stopped
The new drug registration of step pharmaceutical subsidiary was terminated, and 7.6 million R & D expenses have been invested
Pfizer acquired biohaven for about US $11.6 billion to expand the product pipeline of nervous system diseases
Medtronic's world's first self expanding pulmonary valve was first-class recalled
Inactivated vaccine against novel coronavirus of Chinese medicine Zhongsheng Omicron mutant approved for clinical use
Biopharmaceutical Firm Sinogen Raises Tens of Millions of US in Pre-Series B Round
Founded in 2016, Sinogen has established a technology platform to study the mechanisms of an oncolytic virus targeting tumor cells and completed the preclinical study of SGN1, genetic engineering product that can accurately and rapidly dissolve tumors.
May 24, 2022 07:45 PM
Junshi Announces Its Anti-Covid Phase III Drug Reaches Primary Endpoint
Founded in August 2021, Juntuo Biotech is dedicated to the R&D processes in biomedicine and vaccines. The company's innovative R&D pipelines cover viral vaccines, bacterial vaccines, genetically engineered vaccines, conjugate vaccines, and multivalent vaccines.
May 24, 2022 03:45 PM
The new crown inactivated vaccine of Sinopharm Zhongsheng Omicron mutant was approved clinically.
Cinda biology and Baoyuan medicine announced that taretinib was included in the breakthrough therapeutic drug variety
Xinda biology and JinFang medicine have reached global strategic cooperation on KRAS G12C inhibitor gfh925